Ongoing efforts to improve mood disorder therapeutics aimed at overcoming the limitations of SSRIs include the development of reuptake inhibitors that target other monoamine systems, such as dopamine (DA) and norepinephrine (NE) or that do so in combination with SERT antagonism, as well as mixed action molecules that combine SERT inhibition with actions at 5-HT receptors [3, 7]. The gene discussed is SLC6A4; the disease is mood disorder.